Lisata Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lisata Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.5 times its market value (net cash). Higher than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
1.5× cashCash, after subtracting all debt, is 1.5 times its market value (net cash).
Higher than 93% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Lisata Therapeutics, Inc. made a loss over the last year. Lisata Therapeutics, Inc. owes $0.28 for every $1 it owns. Lisata Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLisata Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.32The share price is 1.32 times Lisata Therapeutics, Inc.'s book value per share, lower than 72% of Healthcare companies in United States.
Market cap
$11 MThe total market value of all of Lisata Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 87% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$8 MWhat Lisata Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.76Net worth divided by the number of shares. The share price of $1.01 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-101.7%Lisata Therapeutics, Inc. lost 101.7% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
Owes vs Owns
0.28×Lisata Therapeutics, Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Dividend yield
NoneLisata Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-83%Revenue fell 83% in the year to Dec 2025.
Profit growth
LossLisata Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-9756.5%Lisata Therapeutics, Inc. lost $9756 for every $100 of revenue.
Cash vs debt
Net cashLisata Therapeutics, Inc. held $16 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Lisata Therapeutics, Inc.: $11 M ÷ $8 M (30 Jun 2026) = 1.3.
What is Lisata Therapeutics, Inc.'s return on equity?
Lisata Therapeutics, Inc. lost 101.7% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
How much does Lisata Therapeutics, Inc. owe compared with what it owns?
Lisata Therapeutics, Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Does Lisata Therapeutics, Inc. pay a dividend?
No. Lisata Therapeutics, Inc. does not currently pay a dividend.
Is Lisata Therapeutics, Inc.'s revenue growing?
Revenue fell 83% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.